Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DR-2001a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-2001a | DRUG | DR-2001a administered vaginally each month |
| DR-2001b | DRUG | DR-2001b administered vaginally each month |
| Placebo | OTHER | Placebo administered vaginally each month |
Inclusion Criteria: * Surgically sterilized (patient or partner), willing to use condoms throughout the study, or otherwise not at risk for pregnancy * Diagnosis of endometriosis within the last 5 years * Moderate or severe nonmenstrual pelvic pain * Premenopausal * Not pregnant or breastfeeding * ...
DR-2001a is an investigational small molecule being developed for the treatment of endometriosis. It is specifically being evaluated for the management of endometriosis-related pelvic pain. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of DR-2001a has not been disclosed. It is a small molecule being studied for its potential to manage endometriosis-related pelvic pain. The drug is being developed by Teva Pharmaceutical Industries Limited.
DR-2001a is being developed by Teva Pharmaceutical Industries Limited, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol TEVA. The drug is currently in Phase 2 clinical development for the treatment of endometriosis.
DR-2001a is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the management of endometriosis-related pelvic pain.
DR-2001a has one completed Phase 2 clinical trial, identified as NCT00117481, titled 'Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain'. This randomized, double-blind, placebo-controlled trial enrolled 90 female participants aged 18 years and older in the United States.
DR-2001a is the drug name used in the clinical trial record, while the trial title refers to the drug as DR-2001. These names appear to refer to the same investigational compound being developed by Teva Pharmaceutical Industries Limited for endometriosis.